Submitters Still Confused On Adverse Event Reporting To ClinicalTrials.gov
This article was originally published in The Gray Sheet
Executive Summary
Device and drug firms that submit details about their clinical trials to ClinicalTrials.gov are still having problems reporting adverse events data, Deborah Zarin, the Web site's director, told the FDA Risk Communication Advisory Committee Nov. 12
You may also be interested in...
Regs Or No Regs, FDA Will Seek Adherence To ClinicalTrials.gov Mandates
Manufacturer confusion over ClinicalTrials.gov trial registration and reporting requirements is no excuse for failing to make a good-faith attempt at compliance, FDA and NIH officials say
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.